LAMA2 and ependymoma: LAMA2 has recently been identified as a molecular marker of aggressive ependymoma (34), and a promoter of malignancy in glioblastomas (GBMs) through the maintenance of GBM stem cell compartment; therefore, it can be used as a molecular fingerprint and a possible therapeutic target for GBMs (35).